The Multiple Myeloma Channel is supported with funding from AbbVie (Platinum), Sanofi (Gold), Legend Biotech (Bronze), and through an educational grant from Alexion Pharma GmbH.
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
IMS 2026 | Prognostic value of using NGF to identify aberrant plasma cell subtypes in newly diagnosed myeloma
Alessandro Gozzetti, MD, PhD, Azienda Ospedaliera Universitaria Senese, Siena, Italy, discusses a single-center experience using next-generation flow (NGF) to identify aberrant clonal plasma cell subtypes in newly diagnosed multiple myeloma. Dr Gozzetti highlights that NGF can provide prognostic information through both measurable residual disease (MRD) assessment and the surface antigens expressed on plasma cells, with further research now underway. This interview took place at the 23rd International Myeloma Society (IMS) Annual Meeting in Glasgow, UK.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
